-
Article
Daratumumab plus bortezomib or daratumumab plus lenalidomide as salvage therapy for patients with myeloma: initial follow-up of an Italian multicentre retrospective clinical experience by ‘Rete Ematologica Pugliese’
We report herein a multicentre retrospective analysis of 192 consecutive patients with symptomatic refractory/relapsed multiple myeloma (RRMM) treated with daratumumab in combination with bortezomib or lenalid...
-
Article
Open AccessHigh-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling
To understand neutrophil impairment in the progression from MGUS through active MM, we investigated the function of mature, high-density neutrophils (HDNs), isolated from peripheral blood. In 7 MM, 3 MGUS and ...
-
Article
Water sorption thermodynamics in glassy polymers endowed with hydrogen bonding interactions
In this contribution, we review and critically compare the results of the analyses we have previously performed on water sorption thermodynamics in a series of polyimides. The experimental investigation was pe...
-
Article
Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma
This multicentre, open-label phase 1/2 trial determined safety and efficacy of weekly carfilzomib plus cyclophosphamide–dexamethasone (wKCyd) in newly diagnosed multiple myeloma (NDMM) patients aged ⩾65 years ...
-
Article
Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System
Allogeneic hematopoietic stem cell transplantation (allo-SCT) represents the only curative treatment for patients with myelodysplastic syndrome (MDS), but involves non-negligible morbidity and mortality. Cruci...
-
Article
Do we need to distinguish exosomes from microvesicles in hematological malignancies?
-
Article
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis
In newly diagnosed myeloma patients, upfront autologous transplant (ASCT) prolongs progression-free survival 1 (PFS1) compared with chemotherapy plus lenalidomide (CC+R). Salvage ASCT at first relapse may stil...
-
Article
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease
Identification of patient sub-groups with smoldering multiple myeloma (SMM) at high risk of progression to active disease (MM) is an important goal. 18F-FDG PET/CT (positron emission tomography (PET) integrate...
-
Article
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival
Polymerase chain reaction (PCR)-based minimal residual disease (MRD) analysis is a useful prognostic tool in multiple myeloma (MM), although its long-term impact still needs to be addressed. This report presen...
-
Chapter and Conference Paper
Gold Photonic Crystals and Photonics Quasi-crystals for Reproducible Surface-Enhanced Raman Substrates
Since the initial discovery of surface-enhanced Raman scattering (SERS), an increased amount of work has been done on the research of substrates for highly efficient Raman scattering enhancement due to their e...
-
Article
Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia
-
Article
Analisi dei consumi di due classi di medicinali biotecnologici (ESA e G-CSF) in cinque Paesi europei
The expected benefits of biosimilar drugs (a lower price and a competition effect on originators’ price) offer an opportunity to contain the rising trend of the hospital pharmaceutical expenditure. This paper ...
-
Article
Lenalidomide−prednisone induction followed by lenalidomide−melphalan−prednisone consolidation and lenalidomide−prednisone maintenance in newly diagnosed elderly unfit myeloma patients
This multicenter phase II trial evaluated the safety and efficacy of lenalidomide−prednisone (RP) induction, followed by lenalidomide−melphalan−prednisone (MPR) consolidation and RP maintenance in elderly unfi...
-
Article
Lenalidomide cutaneous adverse event: a case of Stevens–Johnson syndrome (SJS) in a primary plasma cell leukaemia patient treated with lenalidomide and dexamethasone
-
Article
Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets
Bone marrow (BM) angiogenesis has an important role in the initiation and progression of multiple myeloma (MM). We looked at novel mechanisms of vessel formation in patients with MM through a comparative prote...
-
Article
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-Azacytidine
-
Article
Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy
Lenalidomide has raised concerns regarding its potential impact on the ability to collect stem cells for autologous stem cell transplantation, especially after prolonged exposure. The use of cyclophosphamide p...
-
Article
Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study
Alemtuzumab is active in chronic lymphocytic leukaemia (CLL) patients refractory to alkylators and fludarabine. The aim of this study was to determine the efficacy and safety of subcutaneous alemtuzumab at low...
-
Article
Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome
This study evaluated the impact of a new epoetin alfa dosing regimen on quality of life (QOL), transfusion requirements, and hemoglobin (Hb) levels in 133 patients with low-risk myelodysplastic syndrome (MDS) ...
-
Article
Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m2)
Several trials have shown the superior impact of high-dose melphalan (usually 200 mg/m2, MEL200) vs standard therapy in myeloma patients. Intermediate-dose melphalan (100 mg/m2, MEL100) is also superior to the st...
